A carregar...
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
BACKGROUND: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF discontinuation. Alternative dosing strategies may help patients continue their therapy. METHODS: In this multicenter, double-bl...
Na minha lista:
| Publicado no: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846760/ https://ncbi.nlm.nih.gov/pubmed/29563781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S154012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|